Proteomic profile of IPF progression to help tailor treatments
Official title: Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression Trajectory
Funded at University of Michigan at Ann Arbor · NIH-11365030 · Data updated 2026-11-12
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $662,677 |
| NIH project number | 5R01HL169166-04 |
| Project ID | NIH-11365030 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with idiopathic pulmonary fibrosis who can provide blood samples and participate in long-term follow-up.
✕Less likely to help
Patients with IPF for whom blood-based biomarkers do not clarify progression or who cannot participate in follow-up assessments.
What this research studies
This project uses a high-throughput blood test to measure about 3,000 proteins in people with idiopathic pulmonary fibrosis (IPF) to find markers that predict whether their lung function will worsen over a year. Researchers will test these markers in large groups from the PROFILE and Pulmonary Fibrosis Foundation cohorts and use machine learning to build a proteomic signature that forecasts FVC decline. The team will create and validate a quantitative platform to measure the chosen proteins and assess how well the signature predicts disease trajectory in future patients. If successful, the work could enable earlier and more targeted trials and treatment approaches for IPF.
Why it matters
Potential benefit: If the proteomic signature is accurate, doctors could forecast IPF progression more precisely and tailor therapies sooner.
How similar studies have gone: Previous studies have identified blood protein changes in IPF, but this project aims to create a validated predictive signature.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Adrenergic Nerves and Noradrenaline in Lung Fibrosis
A physician-scientist-in-training at Yale seeks to build a patient-focused research program on how nerve signals and adrenaline affect lung scarring in IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.